ifosfamide has been researched along with Cystitis in 62 studies
Cystitis: Inflammation of the URINARY BLADDER, either from bacterial or non-bacterial causes. Cystitis is usually associated with painful urination (dysuria), increased frequency, urgency, and suprapubic pain.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ifosfamide is an oxazaphosphorine analogue of cyclophosphamide with proven activity in breast cancer but substantial urotoxicity." | 9.08 | Evaluation of ifosfamide plus mesna as first-line chemotherapy in women with metastatic breast cancer. ( Hartmann, LC; Ingle, JN; Krook, JE; Mailliard, JA; Wieand, HS, 1995) |
| "Cyclophosphamide (CP) and ifosfamide (IF) are widely used antineoplastic agents, but their side-effect of hemorrhagic cystitis (HC) is still encountered as an important problem." | 8.84 | Pathophysiological aspects of cyclophosphamide and ifosfamide induced hemorrhagic cystitis; implication of reactive oxygen and nitrogen species as well as PARP activation. ( Korkmaz, A; Oter, S; Topal, T, 2007) |
| "Acrolein is the main toxic metabolite of ifosfamide (IFO) that causes urothelial damage by oxidative stress and inflammation." | 8.31 | [8] and [10]-Gingerol reduces urothelial damage in ifosfamide-induced hemorrhagic cystitis via JAK/STAT/FOXO signaling pathway via IL-10. ( Clementino, M; da Silva, JA; de Freitas, TM; Ferreira, FCS; Havt, A; Lima, AAM; Lima, MA; Martins, DS; Mota, MRL; Queiroga, ML; Ribeiro, SA; Rodrigues, FAP; Silva, DO; Veras, HN, 2023) |
| "Hemorrhagic cystitis (HC) is the major dose-limiting adverse effect of the clinical use ifosfamide (IFOS)." | 7.96 | α-Phellandrene attenuates tissular damage, oxidative stress, and TNF-α levels on acute model ifosfamide-induced hemorrhagic cystitis in mice. ( Almeida, FRC; Cunha, FVM; Gonçalves, RLG; Lima-Júnior, RCP; Lopes, ME; Medeiros, JVR; Nogueira, KM; Oliveira, CPC; Oliveira, FA; Oliveira, LSA; Pereira, VMP; Rezende, DC; Sousa, DP; Sousa, IJO; Sousa-Neto, BPS; Souza, LKM; Wong, DVT, 2020) |
| "Ifosfamide and other oxazaphosphorines can result in hemorrhagic cystitis, a constellation of complications caused by acrolein metabolites." | 7.91 | IPSE, a urogenital parasite-derived immunomodulatory protein, ameliorates ifosfamide-induced hemorrhagic cystitis through downregulation of pro-inflammatory pathways. ( Alouffi, A; Banskota, N; Falcone, FH; Hsieh, MH; Ishida, K; Jardetzky, TS; Le, L; Mbanefo, EC; Odegaard, JI; Pennington, LF; Zee, R, 2019) |
| "Hemorrhagic cystitis is an important dose limiting side effect of ifosfamide based cancer chemotherapy." | 7.81 | Target Inhibition of IL-1 Receptor Prevents Ifosfamide Induced Hemorrhagic Cystitis in Mice. ( Alencar, VT; Brito, GA; Cunha, FQ; Leite, CA; Lima-Júnior, RC; Magalhães, PJ; Melo, DL; Melo, PH; Mota, JM; Mourão, LT; Ribeiro, RA; Santos, AA; Wong, DV, 2015) |
| "We investigated whether interleukin-4 (IL-4) is present and capable of reducing inflammatory changes seen in ifosfamide-induced hemorrhagic cystitis." | 7.78 | Interleukin-4 modulates the inflammatory response in ifosfamide-induced hemorrhagic cystitis. ( Brito, GA; Cunha, FQ; Freitas, HC; Lima, RC; Macedo, FY; Mourão, LT; Oriá, RB; Ribeiro, RA; Vale, ML; Wong, DV, 2012) |
| "Ifosfamide (IFS) is often involved in the occurrence of hemorrhagic cystitis due to direct contact of its metabolite acrolein with uroepithelium." | 7.77 | Cyclooxygenase-2 contributes to functional changes seen on experimental hemorrhagic cystitis induced by ifosfamide in rat urinary bladder. ( Brito, GA; Jucá, DM; Lima, RC; Macedo, FY; Magalhães, PJ; Mourão, LT; Neto, Jde S; Palheta, RC; Ribeiro, RA; Santos, AA; Souza, MH, 2011) |
| "Ifosfamide (IFS) is an antineoplastic alkylating agent whose major side effect is hemorrhagic cystitis (HC)." | 7.74 | Amifostine and glutathione prevent ifosfamide- and acrolein-induced hemorrhagic cystitis. ( Batista, CK; Brito, GA; Cunha, FQ; Leitão, BT; Mota, JM; Ribeiro, RA; Souza, MH; Souza, ML, 2007) |
| "Hemorrhagic cystitis (HC) is a limiting side effect of chemotherapy with ifosfamide (IFS)." | 7.74 | Cyclooxygenase-2 expression on ifosfamide-induced hemorrhagic cystitis in rats. ( Almeida, PR; Baltazar, F; Brito, GA; Ferreira, FV; Macedo, FY; Ribeiro, RA; Schmitt, FC; Távora, F, 2008) |
| "Hemorrhagic cystitis (HC) is a limiting side-effect of chemotherapy with ifosfamide (IFS)." | 7.72 | Use of dexamethasone with mesna for the prevention of ifosfamide-induced hemorrhagic cystitis. ( Belarmino-Filho, JN; Brito, GA; Cunha, FQ; Macedo, FY; Nery, EA; Ribeiro, RA; Vieira, MM, 2003) |
| ") in cyclophosphamide (CYP) and ifosfamide (IFS) induced hemorrhagic cystitis (HC)." | 7.72 | Ternatin, a flavonoid, prevents cyclophosphamide and ifosfamide-induced hemorrhagic cystitis in rats. ( Brito, GA; Costa, AC; Cunha, AN; Filho, JN; Macêdo, FY; Ribeiro, RA; Silveira, ER; Vieira, MM, 2004) |
| "We investigated the participation of nitric oxide in ifosfamide induced hemorrhagic cystitis in mice, and the involvement of tumor necrosis factor (TNF)-alpha and interleukin (IL)-1beta in the induction of nitric oxide production in this model." | 7.71 | Tumor necrosis factor-alpha and interleukin-1beta mediate the production of nitric oxide involved in the pathogenesis of ifosfamide induced hemorrhagic cystitis in mice. ( Brito, GA; Campos, MC; Cunha, FQ; Figueiredo, FC; Freitas, HC; Ribeiro, RA; Santos, CC, 2002) |
| "Hemorrhagic cystitis is a major potential toxicity of ifosfamide that can be prevented by administering mesna along with the cytotoxic agent." | 7.69 | Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis. ( Belinson, J; Kennedy, A; Kulp, B; Markman, M; Peterson, G; Webster, K, 1996) |
| "A total of 64 courses of ifosfamide (IFM) treatments for sarcoma patients were evaluated for toxic effects." | 7.68 | [Toxic effects of ifosfamide in the treatment of bone and soft tissue sarcomas]. ( Ishii, T; Kitoh, M; Satoh, T; Tatezaki, S; Umeda, T, 1993) |
| " Hemorrhagic cystitis was not observed in patients treated with 400-500 mg of mesna iv every 4 hours during ifosfamide treatment." | 7.67 | Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma. ( Antman, KH; Montella, D; Rosenbaum, C; Schwen, M, 1985) |
| "One hundred twenty-four children and young adults with recurrent tumors, predominantly sarcomas, were treated with the combination of ifosfamide, etoposide, and the uroprotector, mesna (2-mercaptoethane sulphonate), in a phase II trial." | 7.67 | Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. ( Forquer, R; Jarosinski, P; Kinsella, TJ; Magrath, I; Miser, JS; Triche, TJ; Tsokos, M; Wesley, R, 1987) |
| "We examined the possibility of continuing oxazaphosphorine therapy in patients with previously documented cyclophosphamide- or ifosfamide-induced hematuria by concomitant use of the uroprotective agent, mesna." | 7.67 | The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy. ( Andriole, GL; Arasi, V; Linehan, M; Magrath, IT; Miser, JS; Sandlund, JT, 1987) |
| "To prevent hemorrhagic cystitis induced by ifosfamide, continuous bladder irrigation with 3,000 ml." | 7.66 | Prevention of ifosfamide-induced hemorrhagic cystitis by continuous bladder irrigation. ( Fujita, J; Kakizoe, T; Matsumoto, K; Murase, T, 1981) |
| "Ifosfamide (IFO) is an antineoplastic drug that is commonly used to treat gynecological and breast cancers." | 5.48 | Neutrophils contribute to the pathogenesis of hemorrhagic cystitis induced by ifosfamide. ( Alencar, NMN; Almeida, PRC; Alves, APNN; Araújo, LCNC; Bingana, RD; Cunha, FQ; Dornelas-Filho, AF; Lima-Júnior, RCP; Melo, AT; Nobre, LMS; Nour, ML; Pereira, VBM; Pinto, FMM; Silva, CMS; Silva, PGB; Silva, RO; Souza, MHLP; Wanderley, CWS; Wong, DVT, 2018) |
| "The incidence of IFO-induced HC may be associated with the dosage of IFO." | 5.43 | A retrospective study of treatment and prophylaxis of ifosfamide-induced hemorrhagic cystitis in pediatric and adolescent and young adult (AYA) patients with solid tumors. ( Kumamoto, T; Makino, Y; Ogawa, C; Saito, Y; Tamai, I; Terakado, H, 2016) |
| "Ifosfamide is an oxazaphosphorine analogue of cyclophosphamide with proven activity in breast cancer but substantial urotoxicity." | 5.08 | Evaluation of ifosfamide plus mesna as first-line chemotherapy in women with metastatic breast cancer. ( Hartmann, LC; Ingle, JN; Krook, JE; Mailliard, JA; Wieand, HS, 1995) |
| "The use of oxazaphosphorines (cyclophosphamide, ifosfamide) in the treatment of numerous neoplastic disorders is associated with their essential adverse effect in the form of hemorrhagic cystitis, which considerably limits the safety and efficacy of their pharmacotherapy." | 4.88 | Bladder urotoxicity pathophysiology induced by the oxazaphosphorine alkylating agents and its chemoprevention . ( Dobrek, Ł; Thor, PJ, 2012) |
| "Cyclophosphamide (CP) and ifosfamide (IF) are widely used antineoplastic agents, but their side-effect of hemorrhagic cystitis (HC) is still encountered as an important problem." | 4.84 | Pathophysiological aspects of cyclophosphamide and ifosfamide induced hemorrhagic cystitis; implication of reactive oxygen and nitrogen species as well as PARP activation. ( Korkmaz, A; Oter, S; Topal, T, 2007) |
| "Ifosfamide is relatively well tolerated but it can be associated occasionally with life-threatening complications such as arrhythmias and heart failure, severe encephalopathy and hemorrhagic cystitis." | 4.82 | Side effects of ifosfamide. ( Klastersky, J, 2003) |
| "Acrolein is the main toxic metabolite of ifosfamide (IFO) that causes urothelial damage by oxidative stress and inflammation." | 4.31 | [8] and [10]-Gingerol reduces urothelial damage in ifosfamide-induced hemorrhagic cystitis via JAK/STAT/FOXO signaling pathway via IL-10. ( Clementino, M; da Silva, JA; de Freitas, TM; Ferreira, FCS; Havt, A; Lima, AAM; Lima, MA; Martins, DS; Mota, MRL; Queiroga, ML; Ribeiro, SA; Rodrigues, FAP; Silva, DO; Veras, HN, 2023) |
| "Hemorrhagic cystitis (HC) is the major dose-limiting adverse effect of the clinical use ifosfamide (IFOS)." | 3.96 | α-Phellandrene attenuates tissular damage, oxidative stress, and TNF-α levels on acute model ifosfamide-induced hemorrhagic cystitis in mice. ( Almeida, FRC; Cunha, FVM; Gonçalves, RLG; Lima-Júnior, RCP; Lopes, ME; Medeiros, JVR; Nogueira, KM; Oliveira, CPC; Oliveira, FA; Oliveira, LSA; Pereira, VMP; Rezende, DC; Sousa, DP; Sousa, IJO; Sousa-Neto, BPS; Souza, LKM; Wong, DVT, 2020) |
| "Ifosfamide and other oxazaphosphorines can result in hemorrhagic cystitis, a constellation of complications caused by acrolein metabolites." | 3.91 | IPSE, a urogenital parasite-derived immunomodulatory protein, ameliorates ifosfamide-induced hemorrhagic cystitis through downregulation of pro-inflammatory pathways. ( Alouffi, A; Banskota, N; Falcone, FH; Hsieh, MH; Ishida, K; Jardetzky, TS; Le, L; Mbanefo, EC; Odegaard, JI; Pennington, LF; Zee, R, 2019) |
| "Hemorrhagic cystitis is an important dose limiting side effect of ifosfamide based cancer chemotherapy." | 3.81 | Target Inhibition of IL-1 Receptor Prevents Ifosfamide Induced Hemorrhagic Cystitis in Mice. ( Alencar, VT; Brito, GA; Cunha, FQ; Leite, CA; Lima-Júnior, RC; Magalhães, PJ; Melo, DL; Melo, PH; Mota, JM; Mourão, LT; Ribeiro, RA; Santos, AA; Wong, DV, 2015) |
| "We investigated whether interleukin-4 (IL-4) is present and capable of reducing inflammatory changes seen in ifosfamide-induced hemorrhagic cystitis." | 3.78 | Interleukin-4 modulates the inflammatory response in ifosfamide-induced hemorrhagic cystitis. ( Brito, GA; Cunha, FQ; Freitas, HC; Lima, RC; Macedo, FY; Mourão, LT; Oriá, RB; Ribeiro, RA; Vale, ML; Wong, DV, 2012) |
| "Ifosfamide (IFS) is often involved in the occurrence of hemorrhagic cystitis due to direct contact of its metabolite acrolein with uroepithelium." | 3.77 | Cyclooxygenase-2 contributes to functional changes seen on experimental hemorrhagic cystitis induced by ifosfamide in rat urinary bladder. ( Brito, GA; Jucá, DM; Lima, RC; Macedo, FY; Magalhães, PJ; Mourão, LT; Neto, Jde S; Palheta, RC; Ribeiro, RA; Santos, AA; Souza, MH, 2011) |
| " Groups (N = 6-8) were submitted to right or left paw edema (PE) with carrageenan (100 microg) or Dextran (200 microg), hemorrhagic cystitis with ifosfamide (200 mg/kg, ip) or gastric injury (GI) with indomethacin (20 mg/kg, vo)." | 3.75 | Hind limb ischemic preconditioning induces an anti-inflammatory response by remote organs in rats. ( Gomes, AS; Loiola, RT; Ribeiro, RA; Rocha, EL; Simão, AF; Souza Filho, MV; Souza, MH, 2009) |
| "Ifosfamide (IFS) is an antineoplastic alkylating agent whose major side effect is hemorrhagic cystitis (HC)." | 3.74 | Amifostine and glutathione prevent ifosfamide- and acrolein-induced hemorrhagic cystitis. ( Batista, CK; Brito, GA; Cunha, FQ; Leitão, BT; Mota, JM; Ribeiro, RA; Souza, MH; Souza, ML, 2007) |
| "Hemorrhagic cystitis (HC) is a limiting side effect of chemotherapy with ifosfamide (IFS)." | 3.74 | Cyclooxygenase-2 expression on ifosfamide-induced hemorrhagic cystitis in rats. ( Almeida, PR; Baltazar, F; Brito, GA; Ferreira, FV; Macedo, FY; Ribeiro, RA; Schmitt, FC; Távora, F, 2008) |
| ") in cyclophosphamide (CYP) and ifosfamide (IFS) induced hemorrhagic cystitis (HC)." | 3.72 | Ternatin, a flavonoid, prevents cyclophosphamide and ifosfamide-induced hemorrhagic cystitis in rats. ( Brito, GA; Costa, AC; Cunha, AN; Filho, JN; Macêdo, FY; Ribeiro, RA; Silveira, ER; Vieira, MM, 2004) |
| "Hemorrhagic cystitis (HC) is a limiting side-effect of chemotherapy with ifosfamide (IFS)." | 3.72 | Use of dexamethasone with mesna for the prevention of ifosfamide-induced hemorrhagic cystitis. ( Belarmino-Filho, JN; Brito, GA; Cunha, FQ; Macedo, FY; Nery, EA; Ribeiro, RA; Vieira, MM, 2003) |
| " Three drugs have recently been approved: Gleevec (imatinib mesylate) at a starting dose of 400 or 600 mg daily for the treatment of malignant unresectable and/or metastatic gastrointestinal stromal tumors; Mesnex (mesna) tablets as a prophylactic agent to reduce the incidence of ifosfamide-induced hemorrhagic cystitis, and Zometa (zoledronic acid) for the treatment of patients with multiple myeloma and for patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy." | 3.71 | U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid. ( Cohen, MH; Dagher, R; Griebel, DJ; Ibrahim, A; Martin, A; Pazdur, R; Scher, NS; Sokol, GH; Williams, GA, 2002) |
| "We investigated the participation of nitric oxide in ifosfamide induced hemorrhagic cystitis in mice, and the involvement of tumor necrosis factor (TNF)-alpha and interleukin (IL)-1beta in the induction of nitric oxide production in this model." | 3.71 | Tumor necrosis factor-alpha and interleukin-1beta mediate the production of nitric oxide involved in the pathogenesis of ifosfamide induced hemorrhagic cystitis in mice. ( Brito, GA; Campos, MC; Cunha, FQ; Figueiredo, FC; Freitas, HC; Ribeiro, RA; Santos, CC, 2002) |
| "Hemorrhagic cystitis is a major potential toxicity of ifosfamide that can be prevented by administering mesna along with the cytotoxic agent." | 3.69 | Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis. ( Belinson, J; Kennedy, A; Kulp, B; Markman, M; Peterson, G; Webster, K, 1996) |
| "To prevent hemorrhagic cystitis, mesna is typically injected intravenously (i." | 3.69 | Combined intravenous and oral mesna in outpatients treated with ifosfamide. ( Goodman, TL; Goren, MP; McKenna, LM, 1997) |
| "A total of 64 courses of ifosfamide (IFM) treatments for sarcoma patients were evaluated for toxic effects." | 3.68 | [Toxic effects of ifosfamide in the treatment of bone and soft tissue sarcomas]. ( Ishii, T; Kitoh, M; Satoh, T; Tatezaki, S; Umeda, T, 1993) |
| "This study examined the characteristics of urinary bladder lesions (cystitis) induced by ifosfamide (IF), an antitumor agent, and their inhibition by mesna in rats." | 3.68 | [Ifosfamide-induced urinary bladder lesion and its inhibition by mesna]. ( Kasai, H; Matsui, S; Muraoka, Y; Nara, H; Watanabe, H, 1990) |
| "We examined the possibility of continuing oxazaphosphorine therapy in patients with previously documented cyclophosphamide- or ifosfamide-induced hematuria by concomitant use of the uroprotective agent, mesna." | 3.67 | The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy. ( Andriole, GL; Arasi, V; Linehan, M; Magrath, IT; Miser, JS; Sandlund, JT, 1987) |
| "One hundred twenty-four children and young adults with recurrent tumors, predominantly sarcomas, were treated with the combination of ifosfamide, etoposide, and the uroprotector, mesna (2-mercaptoethane sulphonate), in a phase II trial." | 3.67 | Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. ( Forquer, R; Jarosinski, P; Kinsella, TJ; Magrath, I; Miser, JS; Triche, TJ; Tsokos, M; Wesley, R, 1987) |
| " Hemorrhagic cystitis was not observed in patients treated with 400-500 mg of mesna iv every 4 hours during ifosfamide treatment." | 3.67 | Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma. ( Antman, KH; Montella, D; Rosenbaum, C; Schwen, M, 1985) |
| "Based on clinical data, indicating that chloroacetaldehyde (CAA) is an important metabolite of oxazaphosphorine cytostatics, an experimental study was carried out in order to elucidate the role of CAA in the development of hemorrhagic cystitis." | 3.67 | Chloroacetaldehyde and its contribution to urotoxicity during treatment with cyclophosphamide or ifosfamide. An experimental study/short communication. ( Hilgard, P; Pohl, J; Stekar, J, 1989) |
| "Urotoxic side effects, especially hemorrhagic cystitis, have so far been a limiting factor in the therapeutic use of cyclophosphamide (Endoxan), ifosfamide (Holoxan), and trofosfamide (Ixoten)." | 3.66 | Detoxification of urotoxic oxazaphosphorines by sulfhydryl compounds. ( Brock, N; Pohl, J; Stekar, J, 1981) |
| "To prevent hemorrhagic cystitis induced by ifosfamide, continuous bladder irrigation with 3,000 ml." | 3.66 | Prevention of ifosfamide-induced hemorrhagic cystitis by continuous bladder irrigation. ( Fujita, J; Kakizoe, T; Matsumoto, K; Murase, T, 1981) |
| "Twenty-five women with advanced breast carcinoma refractory to first-line chemotherapy entered a phase II trial to evaluate the efficacy of ifosfamide and carboplatin." | 2.68 | Phase II clinical trial of carboplatin, ifosfamide, with oral mesna for metastatic breast carcinoma. ( Herman, RL; Kelley, AS; Muggia, FM; Russell, CA; Spicer, DV; Turrill, M, 1995) |
| " This review summarizes dosing schedules and the incidence of hematuria in 47 clinical studies, in which oral mesna was given to at least 1,986 patients who received more than 6,475 courses of ifosfamide." | 2.39 | Oral administration of mesna with ifosfamide. ( Goren, MP, 1996) |
| "Novel therapeutic options to treat hemorrhagic cystitis are needed." | 1.51 | IPSE, a parasite-derived host immunomodulatory protein, is a potential therapeutic for hemorrhagic cystitis. ( Akinwale, J; Alouffi, A; Falcone, FH; Hsieh, MH; Jardetzky, TS; Le, LH; Mbanefo, EC; Odegaard, JI; Pennington, LF; Zee, RS, 2019) |
| "Ifosfamide (IFO) is an antineoplastic drug that is commonly used to treat gynecological and breast cancers." | 1.48 | Neutrophils contribute to the pathogenesis of hemorrhagic cystitis induced by ifosfamide. ( Alencar, NMN; Almeida, PRC; Alves, APNN; Araújo, LCNC; Bingana, RD; Cunha, FQ; Dornelas-Filho, AF; Lima-Júnior, RCP; Melo, AT; Nobre, LMS; Nour, ML; Pereira, VBM; Pinto, FMM; Silva, CMS; Silva, PGB; Silva, RO; Souza, MHLP; Wanderley, CWS; Wong, DVT, 2018) |
| "The incidence of IFO-induced HC may be associated with the dosage of IFO." | 1.43 | A retrospective study of treatment and prophylaxis of ifosfamide-induced hemorrhagic cystitis in pediatric and adolescent and young adult (AYA) patients with solid tumors. ( Kumamoto, T; Makino, Y; Ogawa, C; Saito, Y; Tamai, I; Terakado, H, 2016) |
| " The bioavailability is nearly 100% after oral application, and the main metabolites are 4-hydroxytrofosfamide, and 4-hydroxyifosfamide." | 1.32 | Hypersensitivity pneumonitis associated with the use of trofosfamide. ( Hartmann, JT; Kanz, L; Kopp, HG, 2004) |
| " Ifosfamide, although itself the effective antineoplastic drug useful in situations which have proved refractory to cyclophosphamide therapy, has the side-effect toxicities caused by its metabolities that pose clinically a very real problem." | 1.30 | Influence of mesna on urotoxic effects of selected bromosubstituted analogs of ifosfamide. ( Konarski, L; Kowalski, P; Kuśnierczyk, H; Radzikowski, C, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 20 (32.26) | 18.7374 |
| 1990's | 14 (22.58) | 18.2507 |
| 2000's | 13 (20.97) | 29.6817 |
| 2010's | 13 (20.97) | 24.3611 |
| 2020's | 2 (3.23) | 2.80 |
| Authors | Studies |
|---|---|
| Ferreira, FCS | 1 |
| Clementino, M | 1 |
| Rodrigues, FAP | 1 |
| Veras, HN | 1 |
| Martins, DS | 1 |
| Queiroga, ML | 1 |
| Lima, MA | 1 |
| Silva, DO | 1 |
| de Freitas, TM | 1 |
| Ribeiro, SA | 1 |
| Mota, MRL | 1 |
| da Silva, JA | 1 |
| Lima, AAM | 1 |
| Havt, A | 1 |
| Gonçalves, RLG | 1 |
| Cunha, FVM | 1 |
| Sousa-Neto, BPS | 1 |
| Oliveira, LSA | 1 |
| Lopes, ME | 1 |
| Rezende, DC | 1 |
| Sousa, IJO | 1 |
| Nogueira, KM | 1 |
| Souza, LKM | 1 |
| Medeiros, JVR | 1 |
| Wong, DVT | 2 |
| Pereira, VMP | 1 |
| Lima-Júnior, RCP | 2 |
| Sousa, DP | 1 |
| Oliveira, CPC | 1 |
| Almeida, FRC | 1 |
| Oliveira, FA | 1 |
| Kamal, M | 1 |
| Govil, A | 1 |
| Anand, M | 1 |
| Abu Jawdeh, BG | 1 |
| Shah, S | 1 |
| Dornelas-Filho, AF | 1 |
| Pereira, VBM | 1 |
| Nobre, LMS | 1 |
| Melo, AT | 1 |
| Silva, CMS | 1 |
| Wanderley, CWS | 1 |
| Nour, ML | 1 |
| Araújo, LCNC | 1 |
| Silva, RO | 1 |
| Pinto, FMM | 1 |
| Bingana, RD | 1 |
| Souza, MHLP | 1 |
| Alencar, NMN | 1 |
| Silva, PGB | 1 |
| Alves, APNN | 1 |
| Almeida, PRC | 1 |
| Cunha, FQ | 6 |
| Schaeffer, EM | 1 |
| Mbanefo, EC | 2 |
| Le, L | 1 |
| Zee, R | 1 |
| Banskota, N | 1 |
| Ishida, K | 1 |
| Pennington, LF | 2 |
| Odegaard, JI | 2 |
| Jardetzky, TS | 2 |
| Alouffi, A | 2 |
| Falcone, FH | 2 |
| Hsieh, MH | 3 |
| Zee, RS | 1 |
| Le, LH | 1 |
| Akinwale, J | 1 |
| Leite, CA | 1 |
| Alencar, VT | 1 |
| Melo, DL | 1 |
| Mota, JM | 2 |
| Melo, PH | 1 |
| Mourão, LT | 4 |
| Wong, DV | 3 |
| Magalhães, PJ | 3 |
| Santos, AA | 2 |
| Brito, GA | 9 |
| Lima-Júnior, RC | 2 |
| Ribeiro, RA | 11 |
| Saito, Y | 1 |
| Kumamoto, T | 1 |
| Makino, Y | 1 |
| Tamai, I | 1 |
| Ogawa, C | 1 |
| Terakado, H | 1 |
| Matz, EL | 1 |
| Lawson, M | 1 |
| Vasilaras, A | 1 |
| De Vries, A | 1 |
| Mactaggart, P | 1 |
| Nicol, D | 1 |
| Glezerman, IG | 1 |
| Souza Filho, MV | 1 |
| Loiola, RT | 1 |
| Rocha, EL | 1 |
| Simão, AF | 1 |
| Gomes, AS | 1 |
| Souza, MH | 3 |
| Macedo, FY | 5 |
| Palheta, RC | 1 |
| Jucá, DM | 1 |
| Lima, RC | 2 |
| Neto, Jde S | 1 |
| Freitas, HC | 2 |
| Oriá, RB | 1 |
| Vale, ML | 2 |
| de Siqueira, RJ | 1 |
| Freire, WB | 1 |
| Vasconcelos-Silva, AA | 1 |
| Fonseca-Magalhães, PA | 1 |
| Lima, FJ | 1 |
| Brito, TS | 1 |
| Lahlou, S | 1 |
| Pereira, LM | 1 |
| Bem, AX | 1 |
| Teixeira, CG | 1 |
| Grassi, LS | 1 |
| Medeiros, RP | 1 |
| Marques-Neto, RD | 1 |
| Callado, RB | 1 |
| Aragão, KS | 1 |
| Dobrek, Ł | 1 |
| Thor, PJ | 1 |
| Cohen, MH | 1 |
| Dagher, R | 1 |
| Griebel, DJ | 1 |
| Ibrahim, A | 1 |
| Martin, A | 1 |
| Scher, NS | 1 |
| Sokol, GH | 1 |
| Williams, GA | 1 |
| Pazdur, R | 1 |
| Klastersky, J | 1 |
| Vieira, MM | 2 |
| Belarmino-Filho, JN | 1 |
| Nery, EA | 1 |
| Filho, JN | 1 |
| Costa, AC | 1 |
| Cunha, AN | 1 |
| Silveira, ER | 1 |
| Kopp, HG | 1 |
| Kanz, L | 1 |
| Hartmann, JT | 1 |
| Batista, CK | 1 |
| Souza, ML | 1 |
| Leitão, BT | 1 |
| Korkmaz, A | 1 |
| Topal, T | 1 |
| Oter, S | 1 |
| Baltazar, F | 1 |
| Almeida, PR | 1 |
| Távora, F | 1 |
| Ferreira, FV | 1 |
| Schmitt, FC | 1 |
| Mukouda, K | 1 |
| Morikawa, E | 1 |
| Hasegawa, K | 1 |
| Noumi, K | 1 |
| Ohmura, T | 1 |
| Mishima, Y | 1 |
| Kawamoto, M | 1 |
| Inagaki, A | 1 |
| Kamitsuna, A | 1 |
| Yamakido, M | 1 |
| Nishimoto, Y | 1 |
| Koyama, T | 1 |
| Katsuta, S | 1 |
| Watson, RA | 1 |
| Brock, N | 5 |
| Pohl, J | 5 |
| Stekar, J | 5 |
| Czownicki, Z | 1 |
| Utracka-Hutka, B | 1 |
| Slavik, M | 1 |
| Saiers, JH | 1 |
| Fujita, J | 1 |
| Matsumoto, K | 1 |
| Kakizoe, T | 1 |
| Murase, T | 1 |
| Shinozaki, T | 1 |
| Matsushita, M | 1 |
| Kusawake, H | 1 |
| Watanabe, H | 2 |
| Arita, S | 1 |
| Chigira, M | 1 |
| Udagawa, E | 1 |
| Matsumoto, S | 1 |
| Kawaguchi, N | 1 |
| Manabe, J | 1 |
| Kuroda, H | 1 |
| Shimoji, T | 1 |
| Turrill, M | 1 |
| Spicer, DV | 1 |
| Kelley, AS | 1 |
| Herman, RL | 1 |
| Russell, CA | 1 |
| Muggia, FM | 1 |
| Sakuma, H | 1 |
| Satoh, T | 2 |
| Matsumoto, E | 1 |
| Kanno, H | 1 |
| Watanabe, M | 1 |
| Kikuta, A | 1 |
| Suzuki, H | 1 |
| Ishii, T | 1 |
| Umeda, T | 1 |
| Kitoh, M | 1 |
| Tatezaki, S | 1 |
| Ingle, JN | 1 |
| Krook, JE | 1 |
| Mailliard, JA | 1 |
| Hartmann, LC | 1 |
| Wieand, HS | 1 |
| Goren, MP | 2 |
| Markman, M | 1 |
| Kennedy, A | 1 |
| Webster, K | 1 |
| Kulp, B | 1 |
| Peterson, G | 1 |
| Belinson, J | 1 |
| Kuśnierczyk, H | 1 |
| Konarski, L | 1 |
| Kowalski, P | 1 |
| Radzikowski, C | 1 |
| McKenna, LM | 1 |
| Goodman, TL | 1 |
| Bonfante, V | 1 |
| Viviani, S | 1 |
| Devizzi, L | 1 |
| Di Russo, A | 1 |
| Di Nicola, M | 1 |
| Magni, M | 1 |
| Matteucci, P | 1 |
| Grisanti, S | 1 |
| Valagussa, P | 1 |
| Bonadonna, G | 1 |
| Gianni, AM | 1 |
| Campos, MC | 1 |
| Santos, CC | 1 |
| Figueiredo, FC | 1 |
| Brühl, P | 1 |
| Hoefer-Janker, H | 1 |
| Scheef, W | 1 |
| Vahlensieck, W | 1 |
| Niemeyer, U | 1 |
| Scheffler, G | 1 |
| Marti, C | 1 |
| Steiner, R | 1 |
| Viollier, AF | 1 |
| Frustaci, S | 1 |
| Foladore, S | 1 |
| De Pascale, A | 1 |
| Freschi, A | 1 |
| Lo Re, G | 1 |
| Sorio, R | 1 |
| Errante, D | 1 |
| Monfardini, S | 1 |
| Iwasaku-Fujimoto, M | 1 |
| Fujiwara, F | 1 |
| Todo, S | 1 |
| Morioka, Y | 1 |
| Imashuku, S | 1 |
| Antman, KH | 2 |
| Elias, A | 1 |
| Ryan, L | 1 |
| Muraoka, Y | 1 |
| Matsui, S | 1 |
| Nara, H | 1 |
| Kasai, H | 1 |
| Hilgard, P | 1 |
| Sakurai, M | 1 |
| Saijo, N | 1 |
| Shinkai, T | 1 |
| Eguchi, K | 1 |
| Sasaki, Y | 1 |
| Tamura, T | 1 |
| Sano, T | 1 |
| Suemasu, K | 1 |
| Jett, JR | 1 |
| Andriole, GL | 1 |
| Sandlund, JT | 1 |
| Miser, JS | 2 |
| Arasi, V | 1 |
| Linehan, M | 1 |
| Magrath, IT | 1 |
| Kinsella, TJ | 1 |
| Triche, TJ | 1 |
| Tsokos, M | 1 |
| Jarosinski, P | 1 |
| Forquer, R | 1 |
| Wesley, R | 1 |
| Magrath, I | 1 |
| Brade, W | 1 |
| Seeber, S | 1 |
| Herdrich, K | 1 |
| Montella, D | 1 |
| Rosenbaum, C | 1 |
| Schwen, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Remote Ischemic Preconditioning on Restenosis Post Lower Limb Revascularization Angioplasty: A Pilot Randomized Control Trial[NCT02406131] | 40 participants (Anticipated) | Interventional | 2018-04-30 | Suspended (stopped due to logistic issues - no available scans for participants at the moment need to postponed starting dates) | |||
| A Phase II Trial of Apatinib in Relapsed and Unresectable High-grade Osteosarcoma After Failure of Standard Multimodal Therapy[NCT02711007] | Phase 2/Phase 3 | 37 participants (Actual) | Interventional | 2016-03-31 | Completed | ||
| Late Effects of Treatment in Survivors of Pediatric Sarcomas[NCT00006515] | 39 participants (Actual) | Observational | 2000-11-16 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for ifosfamide and Cystitis
| Article | Year |
|---|---|
Review of Advances in Uroprotective Agents for Cyclophosphamide- and Ifosfamide-induced Hemorrhagic Cystitis.
Topics: Antineoplastic Agents, Alkylating; Cyclophosphamide; Cystitis; Hemorrhage; Humans; Ifosfamide; Mesna | 2017 |
Urological implications of cyclophosphamide and ifosfamide.
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Cyclophosphamide; Cystitis; Humans; Ifosfamide; | 2008 |
Bladder urotoxicity pathophysiology induced by the oxazaphosphorine alkylating agents and its chemoprevention .
Topics: Animals; Antineoplastic Agents, Alkylating; Chemoprevention; Cyclophosphamide; Cystitis; Cytoprotect | 2012 |
Side effects of ifosfamide.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain; Cystitis; Drug Interactions; Heart; Hemorrhage; H | 2003 |
Pathophysiological aspects of cyclophosphamide and ifosfamide induced hemorrhagic cystitis; implication of reactive oxygen and nitrogen species as well as PARP activation.
Topics: Acrolein; Antineoplastic Agents; Cell Death; Cyclophosphamide; Cystitis; Cytokines; DNA Damage; Enzy | 2007 |
Oral administration of mesna with ifosfamide.
Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents, Alkylating; Cystitis; Drug Administrat | 1996 |
Comparative activity of ifosfamide and cyclophosphamide.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cystitis; Humans; Ifosfam | 1986 |
8 trials available for ifosfamide and Cystitis
| Article | Year |
|---|---|
[Clinical evaluation of Mitexan in the prevention of urinary tract complications during treatment with Holoxan].
Topics: Clinical Trials as Topic; Cyclophosphamide; Cystitis; Hematuria; Humans; Ifosfamide; Mercaptoethanol | 1981 |
[Ifosfamide-induced hemorrhagic cystitis and its prevention by mesna].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; | 1995 |
Phase II clinical trial of carboplatin, ifosfamide, with oral mesna for metastatic breast carcinoma.
Topics: Adenocarcinoma; Adult; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 1995 |
Evaluation of ifosfamide plus mesna as first-line chemotherapy in women with metastatic breast cancer.
Topics: Aged; Antineoplastic Agents, Alkylating; Breast Neoplasms; Cystitis; Drug Administration Schedule; D | 1995 |
High-dose ifosfamide and vinorelbine as salvage therapy for relapsed or refractory Hodgkin's disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cystitis; Female; Granulocyte Colony-Stimulat | 2001 |
Feasibility and efficacy of arginine 2-mercaptoethanesulfonate (ARGIMESNA) in the prevention of hemorragic cystitis from ifosfamide (IFO).
Topics: Adolescent; Adult; Aged; Cystitis; Female; Hemorrhage; Humans; Ifosfamide; Male; Mesna; Middle Aged | 1992 |
Ifosfamide and mesna: response and toxicity at standard- and high-dose schedules.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Child; Chil | 1990 |
The protective effect of 2-mercapto-ethane sulfonate (MESNA) on hemorrhagic cystitis induced by high-dose ifosfamide treatment tested by a randomized crossover trial.
Topics: Adult; Aged; Clinical Trials as Topic; Cystitis; Female; Hemorrhage; Humans; Ifosfamide; Lung Neopla | 1986 |
47 other studies available for ifosfamide and Cystitis
| Article | Year |
|---|---|
[8] and [10]-Gingerol reduces urothelial damage in ifosfamide-induced hemorrhagic cystitis via JAK/STAT/FOXO signaling pathway via IL-10.
Topics: Animals; Cystitis; Female; Hemorrhage; Ifosfamide; Inflammation; Interleukin-10; Mesna; Mice; Signal | 2023 |
α-Phellandrene attenuates tissular damage, oxidative stress, and TNF-α levels on acute model ifosfamide-induced hemorrhagic cystitis in mice.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Cyclohexane Monoterpenes; Cyst | 2020 |
Severe BK polyomavirus-induced hemorrhagic cystitis in a kidney transplant recipient with the absence of renal allograft involvement.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; BK Virus; Cystitis; Hemorrhage; Humans; | 2018 |
Neutrophils contribute to the pathogenesis of hemorrhagic cystitis induced by ifosfamide.
Topics: Animals; Antineoplastic Agents, Alkylating; Cystitis; Drug Therapy, Combination; Female; Hemorrhage; | 2018 |
Re: Review of Advances in Uroprotective Agents for Cyclophosphamide- and Ifosfamide-Induced Hemorrhagic Cystitis.
Topics: Cyclophosphamide; Cystitis; Hemorrhage; Humans; Ifosfamide; Protective Agents | 2018 |
IPSE, a urogenital parasite-derived immunomodulatory protein, ameliorates ifosfamide-induced hemorrhagic cystitis through downregulation of pro-inflammatory pathways.
Topics: Antineoplastic Agents, Alkylating; Cystitis; Cytokines; Egg Proteins; Gene Expression Profiling; Hel | 2019 |
IPSE, a parasite-derived host immunomodulatory protein, is a potential therapeutic for hemorrhagic cystitis.
Topics: Administration, Intravesical; Animals; Basophils; Cell Line; Cell Proliferation; Cystitis; Disease M | 2019 |
Target Inhibition of IL-1 Receptor Prevents Ifosfamide Induced Hemorrhagic Cystitis in Mice.
Topics: Animals; Cystitis; Dose-Response Relationship, Drug; Drug Synergism; Hemorrhage; Ifosfamide; Inflixi | 2015 |
A retrospective study of treatment and prophylaxis of ifosfamide-induced hemorrhagic cystitis in pediatric and adolescent and young adult (AYA) patients with solid tumors.
Topics: Adolescent; Adult; Child; Child, Preschool; Cystitis; Drug Administration Schedule; Female; Hemorrha | 2016 |
Successful treatment of ifosfamide-induced hyponatremia with AVP receptor antagonist without interruption of hydration for prevention of hemorrhagic cystitis.
Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Antineoplastic Agents, Alkylating; Antineoplastic | 2009 |
Hind limb ischemic preconditioning induces an anti-inflammatory response by remote organs in rats.
Topics: Acute Disease; Animals; Carrageenan; Cystitis; Edema; Hindlimb; Ifosfamide; Indomethacin; Inflammati | 2009 |
Cyclooxygenase-2 contributes to functional changes seen on experimental hemorrhagic cystitis induced by ifosfamide in rat urinary bladder.
Topics: Animals; Antineoplastic Agents, Alkylating; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cystitis; | 2011 |
Interleukin-4 modulates the inflammatory response in ifosfamide-induced hemorrhagic cystitis.
Topics: Animals; Cyclooxygenase 2; Cystitis; Hemorrhage; Ifosfamide; Interleukin-1beta; Interleukin-4; Male; | 2012 |
In-vitro characterization of the pharmacological effects induced by (-)-α-bisabolol in rat smooth muscle preparations.
Topics: Animals; Carbachol; Cystitis; Disease Models, Animal; Duodenum; Ifosfamide; In Vitro Techniques; Inf | 2012 |
Blockade of TRPA1 with HC-030031 attenuates visceral nociception by a mechanism independent of inflammatory resident cells, nitric oxide and the opioid system.
Topics: Abdomen; Acetanilides; Animals; Antineoplastic Agents, Alkylating; Cell Count; Colitis; Cystitis; Di | 2013 |
U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Bone Neoplasms; Cystitis; Diph | 2002 |
Use of dexamethasone with mesna for the prevention of ifosfamide-induced hemorrhagic cystitis.
Topics: Animals; Anti-Inflammatory Agents; Cystitis; Dexamethasone; Disease Models, Animal; Dose-Response Re | 2003 |
Ternatin, a flavonoid, prevents cyclophosphamide and ifosfamide-induced hemorrhagic cystitis in rats.
Topics: Animals; Asteraceae; Cyclophosphamide; Cystitis; Flavonoids; Flowers; Hemorrhage; Ifosfamide; Male; | 2004 |
Hypersensitivity pneumonitis associated with the use of trofosfamide.
Topics: Administration, Oral; Aged; Alveolitis, Extrinsic Allergic; Antineoplastic Combined Chemotherapy Pro | 2004 |
Amifostine and glutathione prevent ifosfamide- and acrolein-induced hemorrhagic cystitis.
Topics: Acrolein; Amifostine; Animals; Antidotes; Antineoplastic Agents, Alkylating; Cystitis; Dose-Response | 2007 |
Cyclooxygenase-2 expression on ifosfamide-induced hemorrhagic cystitis in rats.
Topics: Animals; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cystitis; Drug Therapy, Combination; Etorico | 2008 |
[Ifosfamide in the treatment of small cell carcinoma of the lung].
Topics: Adult; Aged; Carcinoma, Small Cell; Cyclophosphamide; Cystitis; Drug Administration Schedule; Drug T | 1983 |
Ifosfamide: chemotherapy with new promise and new problems for the urologist.
Topics: Acetylcysteine; Cyclophosphamide; Cystitis; Female; Hemorrhage; Humans; Ifosfamide; Kidney Neoplasms | 1984 |
The development of mesna for the inhibition of urotoxic side effects of cyclophosphamide, ifosfamide, and other oxazaphosphorine cytostatics.
Topics: Animals; Antineoplastic Agents; Cyclophosphamide; Cystitis; Erythrocyte Count; Ifosfamide; Mercaptoe | 1980 |
Detoxification of urotoxic oxazaphosphorines by sulfhydryl compounds.
Topics: Animals; Cyclophosphamide; Cystitis; Female; Ifosfamide; Kidney; Mercaptoethanol; Mesna; Rats; Urina | 1981 |
Phase I clinical study of acetylcysteine's preventing ifosfamide-induced hematuria.
Topics: Acetylcysteine; Acrolein; Adenocarcinoma; Carcinoma, Squamous Cell; Cyclophosphamide; Cystitis; Dose | 1983 |
Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention. 2. Comparative study on the uroprotective efficacy of thiols and other sulfur compounds.
Topics: Animals; Cyclophosphamide; Cystitis; Female; Hemorrhage; Ifosfamide; Kinetics; Male; Rats; Rats, Inb | 1981 |
Prevention of ifosfamide-induced hemorrhagic cystitis by continuous bladder irrigation.
Topics: Adult; Aged; Cyclophosphamide; Cystitis; Drug Administration Schedule; Evaluation Studies as Topic; | 1981 |
Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention--I. Experimental studies on the urotoxicity of alkylating compounds.
Topics: Alkylating Agents; Animals; Cyclophosphamide; Cystitis; Dose-Response Relationship, Drug; Female; If | 1981 |
[Combination effect of pirarubicin, ifosfamide, and vincristine sulfate in the treatment of advanced synovial sarcoma--report of a case].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Buttocks; Cystitis; Doxorubicin; Female; Hemo | 1995 |
[The clinical effect of factor XIII on drug-induced hemorrhagic cystitis].
Topics: Adolescent; Child; Child, Preschool; Cyclophosphamide; Cystitis; Factor XIII; Female; Hemorrhage; Hu | 1994 |
[Toxic effects of ifosfamide in the treatment of bone and soft tissue sarcomas].
Topics: Administration, Intravesical; Adolescent; Adult; Aluminum Hydroxide; Bone Neoplasms; Child, Preschoo | 1993 |
Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis.
Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents, Alkylating; Cystitis; Hemorrhage; Huma | 1996 |
Influence of mesna on urotoxic effects of selected bromosubstituted analogs of ifosfamide.
Topics: Administration, Oral; Animals; Cystitis; Edema; Female; Hemorrhage; Ifosfamide; Injections, Intraper | 1997 |
Combined intravenous and oral mesna in outpatients treated with ifosfamide.
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Antineoplastic Agents, Alkylating; Cystitis; Fem | 1997 |
Tumor necrosis factor-alpha and interleukin-1beta mediate the production of nitric oxide involved in the pathogenesis of ifosfamide induced hemorrhagic cystitis in mice.
Topics: Animals; Cystitis; Enzyme Induction; Hemorrhage; Ifosfamide; Interleukin-1; Male; Mice; Nitric Oxide | 2002 |
[Prophylactic alkalization of the urine during cytostatic tumor treatment with the oxazaphosphorine derivatives, cyclophosphamide and ifosfamide].
Topics: Alkalies; Cyclophosphamide; Cystitis; Female; Hemorrhage; Humans; Hydrogen-Ion Concentration; Ifosfa | 1979 |
Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sufosfamide.
Topics: Acrolein; Aldehydes; Animals; Cyclophosphamide; Cystitis; Female; Ifosfamide; Inactivation, Metaboli | 1979 |
[High-dose ifosfamide therapy: systemic use of a mucolytic agent for the reduction of urotoxicity].
Topics: Adult; Cyclophosphamide; Cystitis; Hematuria; Humans; Ifosfamide; Male; Mercaptoethanol; Mesna; Oste | 1979 |
Report on carcinogenesis bioassay of isophosphamide.
Topics: Animals; Carcinogens; Cyclophosphamide; Cystitis; Dogs; Female; Hair; Ifosfamide; Lymphoma; Male; Ma | 1978 |
[Effects of mesna (2-mercaptoethane sodium sulfonate) in children with malignant disease receiving oxazaphosphorine chemotherapy].
Topics: Bone Neoplasms; Child; Cyclophosphamide; Cystitis; Female; Hematuria; Humans; Ifosfamide; Leukemia; | 1990 |
[Ifosfamide-induced urinary bladder lesion and its inhibition by mesna].
Topics: Animals; Cystitis; Dose-Response Relationship, Drug; Female; Ifosfamide; Injections, Intravenous; Ma | 1990 |
Chloroacetaldehyde and its contribution to urotoxicity during treatment with cyclophosphamide or ifosfamide. An experimental study/short communication.
Topics: Acetaldehyde; Animals; Cyclophosphamide; Cystitis; Female; Hemorrhage; Ifosfamide; Male; Mesna; Rats | 1989 |
Ifosfamide and mesna.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cystitis; Hemorrhage; Humans; Ifosfamide; Male; Merc | 1989 |
The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy.
Topics: Adolescent; Adult; Child; Child, Preschool; Cyclophosphamide; Cystitis; Female; Hematuria; Hemorrhag | 1987 |
Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Child; Comb | 1987 |
Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Child; Comb | 1987 |
Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Child; Comb | 1987 |
Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Child; Comb | 1987 |
Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cystitis; Drug | 1985 |